EVALUATE/VANTAGE
Macroeconomic trends in Q4 wiped out biopharma’s stock market gains from earlier in 2018, with the S&P Pharmaceuticals Index the only major biopharma index to finish the year in the black. M&A and product licensing volumes were also down, despite notable deals such as Takeda’s $64bn acquisition of Shire and Bristol-Myers Squibb’s $1bn payment to Nektar. Deal-making slowed in the medtech sector too, with fewer acquisitions closed and a corresponding decrease in venture investment rounds.
- Falling share prices in Q4 turned a 15% nine-month climb for the Nasdaq Biotechnology Index into a 9% year-end decline, while the S&P Pharmaceuticals Index only managed a 5% gain.
- M&A activity hit its lowest level since 2009, with 173 total deals; licensing activity also dropped from 2017 levels by both deal count (112) and value measures ($4.94bn).
- The total value of medtech M&A deals came to $27.4bn, a precipitous decline from 2017’s figure of nearly $100bn.
Conversely, 2018 was a banner year for venture financing, with $16.8bn invested in drug development start-ups. Biotech IPOs set new records, with two of the biggest flotations – Moderna and Allogene – occurring in the final months of the year. Medtech IPOs also flourished in the fourth quarter, giving the smaller players a welcome cash injection. The FDA set records as well, with 62 novel drugs approved, and managed a slight reduction in average approval times.
- 37 drug developers raised over $100m in financing, more than double the number in 2017.
- Biotech IPOs raised a record $7.23bn, with the average amount raised tipping over $100m for the first time.
- A total of $695m was raised by device companies going public in the fourth quarter, more than any other three-month period since Vantage started tracking medtech listings in 2013.
- The FDA’s 2018 class of novel drugs is forecast to sell $24bn by 2023, including new migraine drugs Aimovig, Emgality and Ajovy; Alnylam's RNAi therapeutic Onpattro; and 17 new cancer drugs.
“The progress of biopharma and medtech companies last year paints a mixed picture,” said Amy Brown, co-author of the Vantage Pharma, Biotech and Medtech 2018 in Review report. “However, there are signs of health, if the industry is able to capitalize on them."
To download a complimentary copy of the report, visit http://www.evaluate.com/2018Review .
About Vantage
Vantage, formerly known as EP Vantage,
provides award-winning, thought-provoking news and insights into current
and future developments in the industry, and is the only pharmaceutical
news service underpinned by Evaluate’s commercial intelligence. Visit www.evaluate.com/vantage
for free access to daily, data-driven news for pharma, biotech, and
medtech.
On Twitter: @Vantageanalysis.
About Evaluate Ltd
Evaluate provides trusted commercial
intelligence for the pharmaceutical and medical device industries. For
more information on how we give industry-leading companies the time and
understanding to drive better decisions, visit us at www.evaluate.com
.
On Twitter: @EvaluatePharma, @EvaluateMedtech
View source version on businesswire.com: https://www.businesswire.com/news/home/20190226005215/en/
Contact:
Evaluate and Vantage Jennifer Dinkel +1 617-936-7783 jennifer.dinkel@evaluate.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES: Q1 2025 Results30.4.2025 07:30:00 CEST | Press release
Solid Start to the Year SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including pr
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 03:00:00 CEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 22:03:00 CEST | Press release
A Year of Broad-Based Sales Growth, Expanded Market Share and Increased Profitability, Driven by Strategic Priorities SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 21:32:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
One out of Three Secure Civil IDs Delivered Each Year Is Powered by Thales29.4.2025 16:50:00 CEST | Press release
In a world where identity fraud represents a critical vulnerability for citizens and societies, Thales is leading the transformation of civil identity into a secure and citizen-first service. Through its advanced Civil Identity Suite, Thales enables governments worldwide to protect their citizens, ensuring protection at every stage of the identity journey and for the entire identity chain. Supporting more than 300 national identity programmes and having enrolled over 500 million people, Thales is uniquely positioned to deliver secure and responsible identity solutions. Each year, Thales powers one in three smart civil IDs (official electronic documents) issued worldwide, highlighting the company’s key role in shaping the future of identities and helping governments and citizens transition smoothly to digital. With its Civil Identity Suite, Thalesenables the issuance and management of both physical and digital identities, as well as all means of enrolling citizens and enabling seamless
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom